Prostacyclin for pulmonary hypertension (Q34758143)

4 August 2017

1 reference

title

Prostacyclin for pulmonary hypertension. (English)

1 reference

4 August 2017

Prostacyclin for pulmonary hypertension (English)

0 references

author name string

N S Paramothayan

1

1 reference

4 August 2017

T J Lasserson

2

1 reference

4 August 2017

A U Wells

3

1 reference

4 August 2017

E H Walters

4

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

Cochrane Database of Systematic Reviews

4 August 2017

2003

0 references

published in

1 reference

4 August 2017

issue

3

1 reference

4 August 2017

2

0 references

page(s)

CD002994

1 reference

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002994

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002994

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002994

Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002994

Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002994

Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002994

Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002994

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002994

The place of prostacyclin in the clinical management of primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002994

High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002994

Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002994

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002994

Failure of vasodilator infusion to alter pulmonary diffusing capacity in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002994

Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002994

An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002994

Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002994

10.1002/14651858.CD002994

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference